key: cord-0777821-vtpgobb2
authors: Yigenoglu, Tugce N.; Bascı, Semih; Dal, Mehmet S.; Korkmaz, Serdal; Turgut, Burhan; Altuntas, Fevzi
title: The outcome of COVID‐19 in patients with hematological malignancy
date: 2020-11-01
journal: J Med Virol
DOI: 10.1002/jmv.26607
sha: e7b2956b146621f77b9e3fba360b9c024992ce6a
doc_id: 777821
cord_uid: vtpgobb2

We would like to express our sincere thanks to the author's interest in our paper, and we are also grateful for her to add her invaluable contribution to improving the value of our paper. This article is protected by copyright. All rights reserved.

The outcome of COVID-19 in patients with hematological malignancy Dear Editor,

We would like to express our sincere thanks to the author's interest in our paper, and we are also grateful for her to add her invaluable contribution to improving the value of our paper.

We aimed to demonstrate the high vulnerability of patients with hematological malignancies in a large scale, randomized study. Our study revealed that there is an increased risk of COVID-19-related beyond the scope of our study. We agree with the author that further studies and preventive measures to decrease the mortality rates are crucial for this issue; we are also eagerly waiting for such clinical trials to be finalized in the future. The optimal treatment approaches for COVID-19 have still been investigated by researchers worldwide.

The authors declare that there are no conflict of interests. 

The outcome of COVID-19 in patients with hematological malignancy

The outcome of COVID-19 in patients with hematological malignancy